bioAffinity Technologies (bioAffinity Technologies) Days Payable : 39.24 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies Days Payable?

bioAffinity Technologies's average Accounts Payable for the three months ended in Dec. 2023 was $0.72 Mil. bioAffinity Technologies's Cost of Goods Sold for the three months ended in Dec. 2023 was $1.67 Mil. Hence, bioAffinity Technologies's Days Payable for the three months ended in Dec. 2023 was 39.24.

The historical rank and industry rank for bioAffinity Technologies's Days Payable or its related term are showing as below:

BIAF' s Days Payable Range Over the Past 10 Years
Min: 88.02 Med: 52518.57 Max: 104937.5
Current: 88.02

During the past 4 years, bioAffinity Technologies's highest Days Payable was 104937.50. The lowest was 88.02. And the median was 52518.57.

BIAF's Days Payable is ranked better than
57.97% of 207 companies
in the Medical Diagnostics & Research industry
Industry Median: 68.78 vs BIAF: 88.02

bioAffinity Technologies's Days Payable increased from Dec. 2022 (0.00) to Dec. 2023 (39.24). It may suggest that bioAffinity Technologies delayed paying its suppliers.

bioAffinity Technologies Days Payable Historical Data

The historical data trend for bioAffinity Technologies's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioAffinity Technologies Days Payable Chart

bioAffinity Technologies Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Days Payable

104,937.50

99.64

bioAffinity Technologies Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial								-	-	14,645.63	617.17	39.24

Competitive Comparison of bioAffinity Technologies's Days Payable

For the Diagnostics & Research subindustry, bioAffinity Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bioAffinity Technologies's Days Payable Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Days Payable distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's Days Payable falls into.

bioAffinity Technologies Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

bioAffinity Technologies's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.345	+	0.605)	/	2 )	/	1.74	*	365
=	0.475					/	1.74	*	365
=	99.64

bioAffinity Technologies's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.827	+	0.605)	/	2 )	/	1.665	*	365 / 4
=	0.716					/	1.665	*	365 / 4
=	39.24

bioAffinity Technologies Days Payable Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

bioAffinity Technologies (bioAffinity Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257

Website

https://www.bioaffinitytech.com

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.

Executives

Roby Joyce	director	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles	officer: Chief Operating Officer	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty	officer: Chief Financial Officer	2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards	officer: Chief Financial Officer	30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight	director	6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti	director, officer: Executive Chairman	C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson	director	70 DOPPLER, IRVINE CA 92618
Gary D Rubin	director, 10 percent owner	2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond	director	498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes	director, officer: President, CEO	19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust	10 percent owner	21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji	director	C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel	officer: EVP, Chief Sci. & Med. Officer	8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes	officer: Secretary, EVP, Gen. Counsel	1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter	10 percent owner	28 PARRISH POND LANE, SOUTHAMPTON NY 11968